WO2009143372A3 - Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof - Google Patents

Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof Download PDF

Info

Publication number
WO2009143372A3
WO2009143372A3 PCT/US2009/044893 US2009044893W WO2009143372A3 WO 2009143372 A3 WO2009143372 A3 WO 2009143372A3 US 2009044893 W US2009044893 W US 2009044893W WO 2009143372 A3 WO2009143372 A3 WO 2009143372A3
Authority
WO
WIPO (PCT)
Prior art keywords
raf
methods
compositions
sirna
nucleic acid
Prior art date
Application number
PCT/US2009/044893
Other languages
French (fr)
Other versions
WO2009143372A2 (en
Inventor
Frank Y. Xie
Xiaodong Yang
Original Assignee
Intradigm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intradigm Corporation filed Critical Intradigm Corporation
Publication of WO2009143372A2 publication Critical patent/WO2009143372A2/en
Publication of WO2009143372A3 publication Critical patent/WO2009143372A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

The present invention provides nucleic acid molecules that inhibit A-Raf, B-Raf, and/or C-Raf expression. Methods of using the nucleic acid molecules are also provided.
PCT/US2009/044893 2008-05-21 2009-05-21 Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof WO2009143372A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5496008P 2008-05-21 2008-05-21
US61/054,960 2008-05-21

Publications (2)

Publication Number Publication Date
WO2009143372A2 WO2009143372A2 (en) 2009-11-26
WO2009143372A3 true WO2009143372A3 (en) 2010-03-11

Family

ID=41202667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044893 WO2009143372A2 (en) 2008-05-21 2009-05-21 Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2009143372A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649182A4 (en) * 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc Compositions and methods for increasing erythropoietin (epo) production
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
JP6952594B2 (en) * 2017-12-15 2021-10-20 洋司郎 新津 Cell proliferation inhibitor and pharmaceutical composition for treating or preventing cancer containing it

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050530A2 (en) * 1997-05-09 1998-11-12 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids: synthesis, selection and use
WO2003076651A2 (en) * 2002-03-14 2003-09-18 Qlt Inc. Cancer associated araf1 protein kinase and its uses
WO2006040357A2 (en) * 2004-10-15 2006-04-20 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2008076127A1 (en) * 2006-12-21 2008-06-26 Intradigm Corporation Inhibitory polynucleotide compositions and methods for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050530A2 (en) * 1997-05-09 1998-11-12 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids: synthesis, selection and use
WO2003076651A2 (en) * 2002-03-14 2003-09-18 Qlt Inc. Cancer associated araf1 protein kinase and its uses
WO2006040357A2 (en) * 2004-10-15 2006-04-20 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2008076127A1 (en) * 2006-12-21 2008-06-26 Intradigm Corporation Inhibitory polynucleotide compositions and methods for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARASARIDES M ET AL: "B-RAF is a therapeutic target in melanoma", ONCOGENE, NATURE PUBLISHING GROUP, GB BASINGSTOKE, HANTS, vol. 23, no. 37, 19 August 2004 (2004-08-19), pages 6292 - 6298, XP002493793, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
WO2009143372A2 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
AU2017248555B2 (en) Closed nucleic acid structures
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2010120853A3 (en) Methods and compositions to detect and differentiate small rnas in rna maturation pathway
ZA200904684B (en) Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
WO2010048585A3 (en) Oligomeric compounds and methods
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2009002440A3 (en) Compositions comprising human egfr-sirna and methods of use
WO2009151546A3 (en) Methods for treating spinal muscular atrophy
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
DE602007013223D1 (en) CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION
WO2006088888A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
PH12013502230A1 (en) Multispecific antibodies
WO2012076293A3 (en) Formulations comprising polysiloxanes having nitrogen-containing groups
WO2009152084A3 (en) Adipose tissue-derived stem cells for veterinary use
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2009114724A3 (en) COMPOSITIONS COMPRISING NUCLEAR FACTOR-KAPPA B (NF-ĸB) SIRNA AND METHODS OF USE
WO2009012263A3 (en) Tissue-specific micrornas and compositions and uses thereof
WO2011008495A3 (en) Arginase formulations and methods
EP2274442A4 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
HK1142928A1 (en) Nucleic acid amplification in the presence of modified randomers
WO2007106915A8 (en) Antibodies to egfl7 and methods for their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09751600

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09751600

Country of ref document: EP

Kind code of ref document: A2